{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-031332","form_type":"8-K","ticker":"CELC","cik":"0001603454","company_name":"Celcuity Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.373441+00:00","generated_at":"2026-06-21T23:02:21.887643+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Celcuity Q3 net loss $10.9M ($0.75/sh); Phase 3 VIKTORIA-1 site activation underway","bullets":["Net loss $10.9M ($0.75/sh) vs $6.0M ($0.41/sh) in Q3 2021; adjusted net loss $9.5M ($0.63/sh).","R&D expenses $9.6M, up $4.7M YoY, mainly from VIKTORIA-1 trial initiation and existing trials.","Completed selection of 200 clinical sites for Phase 3 VIKTORIA-1; first site activated; first dosing expected by end of 2022.","FDA granted Breakthrough Therapy designation for gedatolisib in July; $100M private placement to close after first patient dose.","Appointed Polly Murphy to Board; Phase 1b update accepted for December 2022 San Antonio Breast Cancer Symposium."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-031332","json":"https://secwatch.observer/filing/0001493152-22-031332.json","markdown":"https://secwatch.observer/filing/0001493152-22-031332.md","text":"https://secwatch.observer/filing/0001493152-22-031332.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603454/000149315222031332/0001493152-22-031332-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603454/000149315222031332/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:02:21.887643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a1427a5935ed7cb09354b0eaa7d9b47eb3170742","claim":"Celcuity Inc. reported the third quarter ended September 30, 2022 results: net income $10.9 million, or $0.75 loss per share, EPS $0.75 loss per share.","evidence_excerpt":"Net loss for the third quarter of 2022 was $10.9 million, or $0.75 loss per share, compared to a net loss of $6.0 million, or $0.41 loss per share, for the third quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603454/000149315222031332/0001493152-22-031332-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"$10.9 million, or $0.75 loss per share"},{"label":"EPS","value":"$0.75 loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}